Kornimate/medical-research-clean huggingface dataset:
effect of core stabilization exercises and neuromuscular electrical stimulation in patients with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: interstitial lung disease (ild) refers to various diseases that occur idiopathic or secondary to some causes, commonly affecting the lung parenchyma, and present with varying degrees of inflammation and fibrosis. idiopathic pulmonary fibrosis (ipf) progressing with progressive shortness of breath causes a decrease in exercise capacity and quality of life, restrictive changes in pulmonary function tests and a decrease in diffusion capacity. it has been reported that core stabilization exercises improve respiratory function, respiratory muscle strength and functional capacity in healthy individuals and some disease groups. it has also been reported that neuromuscular electrical stimulation (nmes) applied to lower extremity, upper extremity and back or quadriceps muscles reduces dynamic hyperinflation and dyspnea during exercise and increases exercise capacity in copd patients.no studies have been performed using core stabilization exercises and nmes in ipf patients. it can be assumed that this therapeutic intervention may also be useful in ipf. our study was planned to investigate the efficacy of core stabilization exercises and nmes in patients with ipf.

stable idiopathic pulmonary fibrosis will be included in the study from the istanbul yedikule chest diseases and thoracic surgery training and research hospital. patients will be randomized into 2 groups; neuromuscular electrical stimulation (nmes) and core stabilization exercises training group (n: 18): 2 days per week for 6 weeks duration. the demographic measurements, respiratory function test, respiratory muscle strength, dyspnea, 6 minutes walking test, quality of life, depression and clinical characteristics and physical fitness of the patients will be recorded. the following parameters will be evaluated before and after the training of the patients in the two groups.

Eligibility criteria:
inclusion criteria: * clinically stable * having no infection or exacerbation in the last 3 months * having no uncontrolled cardiological, psychological problems * having no neoplasm, sarcoidosis or collagen vascular diseases * having no neurological, inner ear or orthopedic disease * patients who volunteered to study exclusion criteria: * over 75 years, * chronic obstructive pulmonary disease (copd) * acute coronary artery disease, * collagen vascular disease, * pneumoconiosis, * sarcoidosis, * cancer * non-parenchymal restrictive lung disease and other serious comorbid conditions, * oxygen saturation in room air at rest \<80% * during acute exacerbation, * echocardiography rvsp\> 50 mmhg * patients taking more than 20mg corticosteroid per day * contraindications to apply the neuromuscular electrical stimulation (pace maker, sensory defects, etc...)

Keywords: core stabilization exercises
vibration response imaging (vri) in management and evaluation in patients with pleural effusion

Conditions: Pleural Effusion

Summary: the primary purpose of this study is evaluate the vri device's accuracy in diagnosis of pleural effusion (in comparison to chest x-ray and ultrasonography), and to assess the pleural effusion location and size. the vri system uses pressure sensors (electronic stethoscopes) to record the energy created by the airflow in the lungs during breathing.

the accumulation of excess fluid in the pleural cavity of the lungs, known as pleural effusion, is a common clinical condition that may be the result of trauma or disease. diagnosis and management of pleural effusion can be done by x-ray or ultrasound; however x-ray emits radiation, requires a special room and expert personnel, while ultrasound requires a high level of expertise to perform and analyze. the vri device is non-invasive and radiation free. the vri device is a simple method to image the lungs in a regional manner to examine changes that occur during pleural effusion. comparison: x-ray and ultrasonography evaluations of pleural effusion, compared to vri acoustic imaging evaluations.

Eligibility criteria:
inclusion criteria: * able and willing to read, understand, and provide written informed consent; * male or female in the age range of 18-85 years; * subject is suspected to have pleural effusion; * body mass index (bmi) \> 21. exclusion criteria: * chest wall deformation; * spine deformation (including severe scoliosis); * hirsutism; * potentially contagious skin lesion on the back; * skin lesion that would interfere with sensor placement; * cardiac pacemaker or implantable defibrillator;

Keywords: pleural effusion lung sounds acoustic monitoring
pressure injury prediction and education model using a mobile application system

Conditions: Pressure Injury; Wound

Summary: pressure injuries are common in the elderly and patients who reduced physical activities. its complications significantly impact the health care system and social burden, even causing the death rate to be as high as 68%. this study aims to collect medical data regarding pressure injuries during hospitalization for developing the pressure injury prediction and education model using a mobile application system. it can offer a prediction on the risk of pressure injury and be used as a teaching aid for pressure injury care, providing a personalized and evidence-based nursing information platform for patients, caregivers, and health professionals.

this study will conduct a randomized controlled trial among 160 primary caregivers of patients with pressure injuries. they will be randomly assigned to the control group or the experimental group. in the control group, patients are routinely cared for in the ward, and this group will have no intervention. routine care includes face-to-face training and educational pamphlets by the ward nurse. the experimental group will be provided a pressure injury prediction of the patient and personalized care information of pressure injury by a smart care platform. the participants (primary caregivers) will fill out the questionnaires online at admission (baseline-t0)and before the patient is discharged(t1). the questionnaires will collect the following data, including demographic information(only t0), knowledge, self-efficacy, anxiety, depression of pressure injury care(t0\&t1), and satisfaction of the smart care platform(only t1). the time to fill out the questionnaires will be about 10 minutes.

Eligibility criteria:
inclusion criteria: 1. the primary caregiver for patients with pressure injury in the hospital. 2. the primary caregiver must be at least 20 years old, have clear consciousness, express independently, communicate in mandarin and taiwanese, use an android phone by himself, and use a mobile phone application after explanation. exclusion criteria: the primary caregiver has a mental or cognitive impairment, cannot express consciousness clearly, or cannot operate mobile apps.

Keywords: pressure injury wound prediction model mobile application system knowledge of wound care self-efficacy anxiety depression
markers of coronary artery disease during exercise testing

Conditions: Coronary Artery Disease; Cardiovascular Disease

Summary: the main purpose of this study is to examine whether changes in biomarkers during exercise are related to coronary artery disease demonstrated by coronary angiography or echocardiography.

chest pain/discomfort is a common patient complaint in patients referred to outpatient clinics and emergency departments. the initial goal of evaluation is to exclude potential life threatening conditions like coronary artery disease. exercise stress testing is a widely available non-invasive test in patients with chest pain and suspected coronary artery disease. however, the sensitivity and specificity of the test is relatively low. exercise seems to cause an increase in the secretion of b-type natriuretic peptide (bnp), and myocardial ischemia may lead to an even more pronounced increase. investigators aim to examine whether changes in bloodborne biomarkers such as nt-pro-bnp during exercise may improve the accuracy of exercise stress testing in patients with chest pain/discomfort and a clinical suspicion of coronary artery disease. also, investigators aim to examine whether changes in biomarkers during exercise are related to cardiac disease demonstrated by echocardiography. it is known that sudden heavy physical load can trigger myocardial infarction, especially in untrained individuals. the underlying mechanisms are poorly understood and may partly be related to changes in inflammation and haemostasis in patients with coronary artery disease. by measuring markers of inflammation and haemostasis during exercise stress testing, investigators hope to gain new insights into mechanisms responsible for exercise-related myocardial infarction. investigators also aim to do a follow-up study to investigate whether results of the initial examinations can relate to future risk of cardiovascular morbidity and mortality.

Eligibility criteria:
inclusion criteria * patients referred to oslo university hospital ullevål with chest pain/discomfort of unknown etiology and and a clinical suspicion of coronary artery disease. * intermediate or high pre test probability of coronary artery disease. * able to give informed, written consent. exclusion criteria * not able to perform the exercise test. * evidence of acute coronary syndrome. * known coronary artery stenosis where exercise testing is contraindicated. * the presence of known moderate to severe valvular heart disease. * known heart failure or obvious clinical signs of heart failure. * ongoing atrial fibrillation or atrial flutter. * complete or partial bundle branch block. * digitoxin therapy. * pacemaker. * renal insufficiency (s-creatinine \>150 micromol/l). * known pregnancy.

Keywords: coronary artery disease cardiovascular disease exercise stress testing biomarkers nt-pro-bnp
evaluation of ixekizumab using auto-injector or prefilled syringe in participants with moderate to severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. treatment period is followed by 40 weeks optional safety extension.


Eligibility criteria:
inclusion criteria: * present with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to randomization * at least 10% body surface area (bsa) of psoriasis at screening and at randomization * static physician global assessment (spga) score of at least 3 and psoriasis area and severity index (pasi) score of at least 12 at screening and at randomization * candidate for phototherapy and/or systemic therapy * men must agree to use a reliable method of birth control during the study * women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment exclusion criteria: * pustular, erythrodermic, and/or guttate forms of psoriasis * history of drug-induced psoriasis * clinically significant flare of psoriasis during the 12 weeks prior to randomization * concurrent or recent use of any biologic agent * received systemic psoriasis therapy \[such as psoralen and ultraviolet a (puva) light therapy\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization * cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study * have participated in any study with interleukin-17 (il-17) antagonists, including ixekizumab * serious disorder or illness other than plaque psoriasis * serious infection within the last 3 months * breastfeeding or nursing (lactating) women
comparison of video consent versus routine consent for participation in research studies

Conditions: Schizophrenia

Summary: the purpose of this study is to examine a novel technique for improving the informed consent process for participation in research by the older psychiatric population.

this study will test a new method of delivering informed consent procedures to people with schizophrenia. the study has two aims. first, it will examine the impact of a multimedia dvd-based informed consent process on the ability of participants to make decisions regarding participation in research, both after the initial presentation of information and after 1 month. second, it will examine the association between participant personal characteristics and the benefit derived from the dvd-based informed consent process. participants with schizophrenia and a normal comparison group will participate in either a routinely used informed consent procedure or an enhanced, dvd-based informed consent procedure. the outcome measure, comprehension of the consent materials, including understanding of the risks and benefits of participating in the study, will be assessed in each group. it is expected that the normal control group will reach the requisite level of comprehension faster than the schizophrenia group.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of schizophrenia or no current or past major neuropsychiatric disorder (normal subjects) * fluency in english * written informed consent exclusion criteria: * known or suspected dementia

Keywords: dvd multi-media schizophrenia normal comparison consent procedures
fecal calprotectin in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: elevated fecal calprotectin is a biomarker for intestinal inflammation in cystic fibrosis


Eligibility criteria:
inclusion criteria: * all patients exclusion criteria: * informed consent/assent not obtained

Keywords: cystic fibrosis calprotectin elastase
multicenter orthopaedic outcomes network (moon) acl reconstruction (aclr): onsite follow-up

Conditions: Rupture of Anterior Cruciate Ligament; Osteoarthritis

Summary: in this study we will examine patients who have undergone unilateral acl reconstruction surgery to determine which structural and functional characteristics of the knee two and ten years post reconstruction surgery, aspects of the original injury and repair, and patient characteristics are risk factors for osteoarthritis after acl reconstruction surgery.

the purpose of this study is identify risk factors for signs and symptoms of osteoarthritis two and ten year post acl reconstruction from information available at the time of surgery; including patient characteristics (age, gender, body mass index (bmi), activity level, clinical knee alignment), their injuries ("pop" heard at the time of injury, concurrent meniscus, articular cartilage, and collateral ligament injuries), and treatment decisions made during the initial surgery (e.g. meniscus and articular cartilage treatments.) primary outcome measures will be the western ontario and mcmaster universities arthritis index (womac) pain and stiffness subscales and joint space width measured on weight-bearing radiographs. secondary outcome measures will include the knee related quality of life subscale of the knee injury and osteoarthritis score (koos) and kellgren-lawrence grading from weight-bearing radiographs.

Eligibility criteria:
inclusion criteria: * had primary unilateral acl reconstruction performed by dr. kurt spindler (vanderbilt university), dr. christopher kaeding (the ohio state university), dr. rick parker (cleveland clinic), dr. jack andrish (cleveland clinic), dr. rick wright (washington university in st. louis), or dr. matthew matava (washington university in st. louis) * 14-55 years of age at the time of follow-up exclusion criteria: * less than 14 years or greater than 55 years * non-active or unable to participate for health reasons

Keywords: anterior cruciate ligament / injuries anterior cruciate ligament / surgery knee injuries / surgery outcomes research prospective studies osteoarthritis
6mw3511 in patients with advanced solid tumor

Conditions: Solid Tumors

Summary: this is a phase i/ii , open-label, multicenter single arm study designed to evaluate the safety, tolerability, pharmacokinetic (pk), and immunogenicity of 6mw3511.

this is a phase i/ii, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. the study consists of a dose escalation phase to determine the maximum tolerated dose (mtd), or recommended phase 2 dose (rp2d) for 6mw3511, and a dose expansion phase which will characterize treatment of 6mw3511 at the rp2d.

Eligibility criteria:
inclusion criteria: 1. in dose-escalation cohorts, histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.in the dose-expansion cohorts , histologically or cytologically confirmed selected advanced solid tumors (to be determined). 2. male or female subjects aged over 18 years old (inclusive) and not more than 80 years old (inclusive). 3. eastern cooperative oncology group (ecog) performance score of 0 or 1. exclusion criteria: 1. history of other malignant tumors within 3 years, except for the tumors that had been cured. 2. symptomatic or active central nervous system metastasis. 3. patients with active autoimmune disease. 4. history of allogeneic hematopoietic stem cell transplantation or organ transplantation. 5. patients previously treated with pd-（l）1/ tgf-β antibody or combined pd-（l）1 with tgf-β antibody. 6. pregnant or breast feeding.
androgen deprivation therapy +/- bevacizumab for psa recurrence of prostate cancer after definitive local therapy

Conditions: Prostate Cancer

Summary: the purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising psa without metastases).

* participants will be randomized into one of two study groups. the first group will receive androgen deprivation therapy (adt) plus bevacizumab. the second group will receive adt alone. * for the androgen deprivation therapy either (treating physician discretion)leuprolide or goserelin acetate (given as injections) every 3 months for a total of 6 months. bicalutamide will also be taken orally daily for a total of 6 months. * bevacizumab will be given intravenously every three weeks for a total of 8 infusions over 6 months. * participants will be evaluated every 7-9 weeks with vitals, physical exam, ps, laboratories including psa and testosterone.

Eligibility criteria:
inclusion criteria: * history of biopsy documented prostate cancer (any gleason score) * past treatment with prostatectomy with or without salvage prostate/pelvic radiation or primary radiation (external beam or brachytherapy) * if past prostatectomy, pathologic stage no greater than t1-3, n1, m0 * psa recurrence with psadt \< 18 months. there is no minimum psa for prostatectomy patients. for patients treated with primary radiation therapy psa should be greater than 2.0 ng/ml * no evidence of recurrent disease on exam, bone scan, ct/mri abdomen/pelvis or cxr * prior adt allowed if \< 6 months and testosterone recovered to within 50 units (ng/dl) of normal range * ecog performance status of 0-1 * absolute neutrophil count of \>1,500 * platelet count \> 100,000 * hg \> 8g/dl * no history of bleeding or thromboses within the last 12 months that required medical intervention exclusion criteria: * history of cancer within 5 years, other than prostate cancer and non-melanoma skin cancer * medical condition requiring concomitant corticosteroids * active infection * prior chemotherapy allowed if was \ 6 months prior to study entry * documented local recurrence or metastatic prostate cancer * inability to comply with study and/or follow-up procedures * life expectancy of less than 2 years * current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a genentech-sponsored bevacizumab cancer study

Keywords: androgen deprivation therapy adt bevacizumab
valvuloplasty scoring balloon catheter first-in-man study

Conditions: Aortic Valve Stenosis

Summary: the valvuloplasty scoring balloon first-in-man study is a prospective, single arm, two phase, observational registry to demonstrate the safety and efficacy of the valvuloplasty scoring balloon catheter for the treatment of critical aortic valve stenosis.

phase 1 will enroll patient who are scheduled to undergo open surgical aortic valve replacement and will have the valvuloplasty scoring balloon delivered to their stenotic aortic valve through a standard aortotomy and deployed immediately prior to valve replacement. phase 2 will enroll patients with aortic valve stenosis who are deemed to not be suitable candidates for elective surgical aortic valve replacement and in whom the investigational valvuloplasty scoring balloon will be used as a stand-alone valvuloplasty procedure or "bridge" to trans-catheter aortic valve implantation (tavi) or surgery.

Eligibility criteria:
inclusion criteria: * native, degenerative-calcific, tricuspid, aortic valve stenosis with echocardiographic derived criteria: mean gradient of \>40 mm hg or doppler peak systolic velocity greater than 4.0 m/s or an initial aortic valve area \< 0.8 cm2. * symptomatic aortic valve disease as demonstrated by ccs functional class ii or greater * aortic valve annulus of greater than or equal to 18 mm and less than or equal to 28 mm measured on pre-procedure tte. * phase 1 patients must be scheduled for a surgical aortic valve replacement. * phase 2 patients must not be suitable candidates for elective surgical aortic valve replacement. exclusion criteria: * recent myocardial infarction (\<30days) * unicuspid or bicuspid aortic valve or non-calcific aortic valve stenosis * any sepsis, including active endocarditis * concomitant 2+ or greater aortic valve valve regurgitation * lvef \< 20% * cva or tia within the previous 6 months * previous aortic valve replacement (bioprosthetic or mechanical)